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morning stiffness), BASFI, ASQoL and the SF-36. Literature review, and clinician 
and patient interviews, provided information on instrument content validity. 
Statistical analysis of measurement properties evaluated the reliability (test-
retest and internal consistency), responsiveness and construct validity. 
Measurement properties were assessed using data from the RAPID-axSpA trial 
investigating certolizumab pegol (CZP) efficacy in axSpA. RESULTS: Reviewed AS 
literature revealed relevant concepts: physical function, pain, disease activity, 
morning stiffness, fatigue, disturbed sleep, depression, mobility problems, 
problems performing recreational activities/household tasks/self-care/work, and 
problems socializing. The same concepts were evident for the overall axSpA 
population in expert interviews. Concepts identified in patient interviews were 
consonant with both literature and expert opinion. All PRO instruments were 
satisfactorily reliable in the RAPID-axSpA population, with all test-retest intra-
class correlation coefficients and internal consistency Cronbach’s alphas >0.8. 
Validity was supported by agreement between PRO and clinician-rated 
measures. All the PRO measures showed good sensitivity to change, with large 
response sizes (effect size >0.8) on almost all measures from week 12 in RAPID-
axSpA. No significant variations in psychometric properties were noted between 
axSpA sub-populations. CONCLUSIONS: This study indicates that both the 
content validity and the measurement properties of PRO instruments used in AS 
are preserved in the broad axSpA population. Questions remain about relying on 
classical test theory for validation and the value of using generic outcome 
measures when well-developed disease-specific measures are available.  
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OBJECTIVES: Lead-time time trade-off (TTO) is a promising alternative to 
conventional TTO. The purpose of this study was to compare the values of EQ-
5D-5L health states as measured by two TTO variants using different ratios of 
lead time to unhealthy time. METHODS: Data were collected as part of a wider 
multi-country pilot study. We elicited the values of 10 selected EQ-5D-5L health 
states from a convenience general population sample (N=406) using two lead-
time TTO variants: 10 years of lead time in full health preceding 5 years of 
unhealthy time (standard method), and 5 years of lead time preceding 5 years of 
unhealthy time (experimental method). Participants self-completed the tasks 
using personal computers, with an interviewer supervising groups of 
participants. Participants were randomized to receive one of the two TTO 
variants to value a block of 5 EQ-5D-5L states. The TTO values were compared 
between the two study arms using random-effects linear models, with 
adjustment of age, gender, education, and health states. RESULTS: Health-state 
values generated from TTO valuation exercises using the longer lead time were 
slightly lower than those generated from exercises using the shorter lead time. 
The proportion of non-negative values in the standard and experimental arms 
was 81.2% and 86.7%, respectively (p=0.046); the grand mean TTO value was 0.35 
and 0.43 for the standard and experimental arms, respectively (p=0.049). 
Exhaustion of tradable time occurred only in the experimental arm (0.46%) 
where the lead time was shorter. CONCLUSIONS: This study confirms earlier 
findings that the ratio of lead time to time in poor health exerts an effect on TTO 
values of health states. The more lead time is offered, the more time is traded. 
Different lead-time TTO variants should be carefully studied in order to achieve 
the best measurement of health-state values using this new method.  
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OBJECTIVES: Time preferences and discounting has become indoctrinated in the 
evaluation of health care technologies that generate future benefits and costs. 
Moreover, it remains a fundamental economic concept that is relied upon for the 
understanding of individuals’ decision making with respect to health. The aim of 
this paper is to provide a systematic review of the empirical studies that have 
attempted to measure either individual or societal inter-temporal preferences 
regarding health. METHODS: A systematic search of peer-reviewed articles 
published in English during 1980 to 2012. The Preferred Reporting System for 
Systematic Reviews and Meta-Analysis (PRISMA) strategy was followed to ensure 
systematic selection of the papers. Articles were excluded if they did not report a 
discount rate or factor(s); and if health (and or life years) was not the domain for 
which discount estimates were provided. Two reviewers assessed the results of 
the search against a predefined exclusion and inclusion strategy to ensure 
appropriate inclusion of papers. RESULTS: A total 64 studies were identified 
within 54 published articles. A variety of methodological approaches have been 
implemented to measure preferences as well as testing over a variety of 
functional forms including hyperbolic and quasi-hyperbolic models. Estimates 
for a constant discount rate vary significantly from below zero to over 1000%. 
However, a weight of evidence in support of hyperbolic or at least non-constant 
discounting is emerging. Evidence is equivocal at best with regards to the 
relationship between time preferences measured and health behaviors. 
CONCLUSIONS: It has become common practice, and is often advised, that 
economic models of future costs and consequences should conduct sensitivity 
analyses regarding the discount rate chosen. From the empirical evidence it 
appears as important that such models also consider the sensitivity of models to 
other debatable concepts regarding discounting including the use of hyperbolic 
functions.  
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OBJECTIVES: Optimizing the clinical trial design and establishing the appropriate 
populations early in development are essential to substantiating a compelling 
value proposition. This project sought to provide an example of how a 
subpopulation investigation can inform early development strategy. METHODS: 
US 2012 National Health and Wellness Survey data were used. Respondents with 
pain in the past month were included. The distribution of work productivity 
(using the WPAI questionnaire) was examined and subpopulations of pain 
patients with particularly high or low impairment were described and compared 
to uncover groups with the highest likelihood of showing incremental benefit 
substantial enough to demonstrate value and compel funding. RESULTS: A total 
of 24,215 respondents (34.0%) reported pain in the past month (mean age=49.96; 
51.92% were female). Mean level of pain severity in the last week was 4.71 
(SD=2.72) and mean overall work productivity loss was 22.04% (SD=27.84%). 
Although these variables were significantly related (r=0.45, p<0.05), a substantial 
percentage of people with pain reported no work impairment (44.23%) creating a 
floor effect whereby regardless of the improvement in pain, no effect would be 
observed with respect to the ability to work. Conversely, 3.6% of people with pain 
reported 90% or more of their work week being impaired. Few demographic 
differences (age, sex) were observed between these two extremes, though those 
with 90%+ impairment were more likely to be obese (43.40%) versus those 
without any impairment (32.80%). CONCLUSIONS: Pain severity and work 
productivity loss were significantly related but many of those with pain reported 
so little impairment that no intervention could provide a compelling proposition. 
However, key subgroups (e.g. those obese) reported significant impairments with 
a much greater likelihood of demonstrating treatment benefit. Subgroup analysis 
early in development can identify the most relevant patient populations and 
help inform clinical trial design, optimize incremental value, and drive cost 
effectiveness.  
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OBJECTIVES: The Rey Auditory Verbal Learning Test (RAVLT) is a cognitive test 
assessing verbal learning and memory. Fifteen words (List A) are presented 
across five learning trials and queried during two delayed-recall trials. A second 
15-word list (List B) designed to interfere with recollection of the primary list is 
used. A recognition trial is administered during which subjects are asked to 
detect List A words from amidst distractor words from List B plus 20 others that 
have a semantic and/or a phonetic link with words from the lists. The objective 
of this abstract is to present the translation process of the RAVLT into Japanese. 
METHODS: For the 30 words from the two lists a direct translation was 
recommended based on collaborative efforts involving a speech therapist and a 
neuropsychologist. The goal was to maintain similar frequency of use and 
syllables (±1 syllable or ±2 syllables and ±2 characters) to the source English 
terms. For the 20 additional words used in the recognition trial, the translations 
had to respect the semantic and/or phonetic links to the words from the two 
lists. RESULTS: Discussions ensued around six of the 30 words from the lists due 
to difficulties in finding direct translations with the appropriate number of 
syllables. For the recognition words, the most problematic issue was finding 
equivalents maintaining the phonetic link to the Japanese translation. Ten 
recognition words had to be changed to uphold this linguistic property. For 
instance, the recognition word “Tree” required a phonetic link to the recall word 
“Turkey” so it was translated as “Box” (Ha Ko) to preserve the phonetic link with 
the word chosen to replace “Turkey” (i.e., “Pigeon” (Ha To)). CONCLUSIONS: This 
methodology enabled the production of a Japanese version of the RAVLT that 
preserved the intent and integrity of the source US English test.  
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OBJECTIVES: According to PhRMA, 75% of Americans are non-adherent on one or 
more of their medications. Low adherence leads to worsening of the disease and 
unnecessary health care spending. Various tools have been used by health care 
professionals to improve medication adherence. The objective of this study is to 
conduct a systematic review to identify tools used to improve medication 
adherence and their impact on medication adherence. METHODS: PRISMA 
guidelines were followed for conducting a systematic review. A comprehensive 
electronic search of research databases (PubMed, MEDLINE, EBSCO, and 
PsycINFO), was performed. Combinations of search terms were generated by 
reviewing existing literature and consulting an expert librarian. Search terms 
included the names of each tool, adherence, compliance, persistence, and 
medication adherence. Studies were included if they were conducted after 
January 2000; involved the use of an adherence tool recommended by a certified 
health care professional; and measured the rate of medication adherence as an 
outcome. Studies on measuring adherence to vaccines and lifestyle 
modifications were excluded. RESULTS: Preliminary search yielded 637 articles. 
Articles were excluded following a title review (552) and an abstract review (43). 
Forty-two studies met the criteria for full review. Six different adherence tools 
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were used. Of these, 27 studies used telephone and text reminders. Four used 
educational materials and books while another four used blister packing. Three 
studies used interactive voice response system, two studies used letters and 
faxes, and another two studies used pill boxes. Improvement in medication 
adherence was found in all studies. The largest change in medication adherence 
was observed through the use of telephone and text reminders. CONCLUSIONS: 
Medication adherence is a problem that pharmacists are addressing through 
health care reform legislation. It’s important for pharmacists/researchers to 
educate about effective adherence tools in order to improve quality of care to 
patients and society.  
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OBJECTIVES: To explore evidence of the degree of correlation between patient 
reported outcomes (PROs) and clinician reported outcomes (ClinROs), and how 
this varies by therapeutic area, measure and language. METHODS: A review of 
the literature and analysis of existing patient registry data was conducted to 
qualitatively assess degree of correlation between PROs and ClinROs – at points 
in time, change over time, and how the relationship between these assessments 
varies by disease area and measure. A review of translation and linguistic 
validation projects involving PRO and ClinROs was also conducted to examine 
language-related differences and correlations between the scales. Specific 
examples of PRO-ClinRO pairs are given for multiple sclerosis, rheumatoid 
arthritis, and atopic eczema, among others. RESULTS: For multiple sclerosis and 
rheumatoid arthritis, moderate correlation (0.5-0.7) was found between patient 
assessments of disease severity and physician assessment, with patient 
assessments influenced by concomitant feelings (e.g., depression, anxiety). The 
correlation between patient and clinician assessment of change/responsiveness 
depends on whether an improvement or deterioration is experienced, where 
deterioration has a perceived stronger impact, patient-wise, than an 
improvement. Differences in language complexity and terminology between 
PROs and ClinROs were essential for the appropriate comprehension by the 
target population. Clinically appropriate and current terminology used for 
ClinROs was key to clinicians accepting the scale as relevant. Simple, clear 
phrasing and wording with language with lower education level was important 
for PROs. CONCLUSIONS: For reviewing PROs and ClinROs, specific differences in 
language and terminology must be taken into account, both in the development 
of instruments and linguistic validation into various target languages. In some 
disease areas, a significant and strong correlation of patient’s assessment with 
objective clinical measures may support its use as a valid proxy measure of 
clinical status, thus opening up multiple research design opportunities where 
the perspective of the patient is paramount.  
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OBJECTIVES: Crohn’s disease (CD) is an inflammatory bowel disease affecting 
approximately 1.4 million people in the United States. The aims of this study 
were to document current unmet needs in CD in terms of patient-reported and 
economic burden; and how such concepts may be assessed to capture the overall 
benefit of new CD therapies for patients, health care systems and society. 
METHODS: Articles were identified in MEDLINE, EMBASE, EconLit, HEED, CRD 
databases and PSYCINFO using pre-defined search terms/limits. 561 abstracts 
were identified; and 31 full articles were reviewed. Direct and indirect costs of 
CD were extracted as were patient-relevant concepts (symptoms and impacts) to 
form a patient-relevant conceptual model. Patient-reported measures were 
identified in PROQOLID and were assessed in context of FDA guidance. RESULTS: 
CD symptoms manifest primarily as gastrointestinal disturbances including 
abdominal pain/cramping and diarrhoea. Fever, fatigue and weight loss are also 
prominent symptoms. These symptoms impact patients’ physical functioning, 
daily activities, emotional well-being, and ability to work. Seven patient-reported 
measures were reviewed in-depth; measures of HRQoL (IBDQ, SF-36, IBDQOL), 
occupational functioning (CPWDQ, WPAI:CD) and disease activity/symptoms 
(CDAI, CDAI-short, GSRS). Instruments to assess HRQoL and occupational 
functioning used concurrently with the CDAI may demonstrate the wider 
influence of treatment on other symptoms and patients’ lives. CD is associated 
with substantial direct costs, estimated at $18-$19,000 per-patient per-year in the 
US, and indirect costs, estimated at $7,260 per-patient per-year. Costs are 
especially high in sub-groups (e.g. presence of fistulas). CONCLUSIONS: The 
disease course of CD is characterised by remissions and relapses, thus lifetime 
humanistic and economic burden is substantial. This review highlights the need 
for disease-specific patient-reported measures that provide comprehensive 
assessment of relevant domains of disease activity/symptoms, HRQoL and 
occupational functioning. Further research into drivers of direct and indirect 
costs of CD is necessary to meet cost-effectiveness requirements.  
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OBJECTIVES: The FDA approved 39 new molecular entities (NMEs) in 2012, and 
many efficacy claims were supported by patient-reported measures or 
statements. In addition, many previously-approved products were approved for 
a new indication supported by PRO endpoints in recent years. The purpose of our 
research was to conduct an in-depth analysis of recently approved claims 
supported by PROs in order to identify notable trends, and to describe best 
methods for assessing the success rate of PRO inclusion. METHODS: Published 
FDA product labels, literature and Internet searches were utilized. All labels of 
NMEs and new indications approved by the FDA from 2010 to 2012 were 
reviewed. A measure or statement of efficacy was considered to be a PRO if it 
assessed symptoms, reduced side effects, or impacts on functioning from the 
patient’s perspective. RESULTS: There were 21, 30, and 39 NMEs approved in 
2010, 2011, and 2012. In these years, 12, 19, and 13 NME labels contained PRO-
related claims or statements (67%, 63%, 33%), and pain-related PROs were the 
most common (n’s=4, 11, 8). Cumulative distribution function (CDF) graphs were 
present in 13 NME labels during these years. Importantly, from 2010 to 2012 
many products added indications with efficacy claims supported by a PRO, but 
such a submission was not considered an NME (e.g., pregabalin). From 2006 to 
2009, PRO-related claims were included in 66% of approved NMEs. This rate 
decreased to 49% during 2010 – 2012; however, more PRO claims (44 versus 50; 
2010-2012) are revealed when reviewing more than NMEs. CONCLUSIONS: 
Development, testing, and validation of PRO measures as clinical trial endpoints 
remain important for facilitating the approval of drugs and communicating value 
to the consumer. Reviewing NDA and BLA labels is a more accurate assessment 
of the success of PRO inclusions in FDA-approved labels than reviewing NMEs 
alone.  
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OBJECTIVES: Apply data mining techniques to pharmacy data to identify 
patients likely to be non-adherent to their medication in the next six months. 
METHODS: Catalina Health™ receives a nationally representative sample of 
pharmacy data containing 40% of all U.S. retail prescription volume and 130 
million unique patient ID’s. The data is HIPAA compliant, longitudinal, and not 
projected. Select 7 prescription medications representing multiple therapeutic 
classes. For each medication, randomly select a 100K patient cohort filling a 
prescription between June and August 2010. In order to eliminate patients who 
switch pharmacies or migrate to mail order, exclude patients who have no 
history of filling any drug during the prior 18 months, or who have no fill history 
for any drug during the six month analysis period. Fit logistic regression models 
to predict which patients will be non-adherent to their medication in the next 
six months. Consider patients non-adherent when Proportion of Days Covered 
(PDC)<80%. Model covariates include prior adherence to the medication (if 
applicable), adherence for co-morbid conditions, days supply of the medication, 
ethnicity and income variables, patient age and gender, paid with cash, number 
of refills remaining, medication dose, and number of co-morbidities. Model 
accuracy is assessed using a 20% hold-out of the data. RESULTS: The models 
identified 40.3% of the patients as likely to be non-adherent to their medication 
in the next six months. This varied by medication (23.2% - 64.6%) and patient 
type (28.8% Experienced, 38.9% Moderate Experienced, and 77.5% New). The 
overall model accuracy rate is 70.4%. 72.3% of the patients predicted to be non-
adherent were actually non-adherent (precision), while 69.1% of the patients 
predicted to be adherent were actually adherent. CONCLUSIONS: Data mining 
techniques applied to pharmacy data can predict patients who are likely to be 
non-adherent to their medication in the next six months with 72.3% precision.  
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OBJECTIVES: Guidelines had present many management recommendations to 
physicians on angina prevention and treatment. However patients still knew less 
about angina management in China. They need Heart education. Thus, we want 
to develop an angina patient self-management questionnaire (ASMQ). 
METHODS: We hypothesized the questionnaire should carry messages of risk 
factors, prevention and treatment of angina. Items were determined from 
guidelines, and interview of patients and cardiovascular doctors. A five point 
Likert scale was chosed as the response format. Higher score means better 
management. The questionnaire was tested along with a cross-sectional angina 
study. Reliability was evaluated via internal consistency, and test-retest 
reliability. Construct validity was tested through Exploratory Factor Analysis 
(EFA), and discriminant validity was assessed by detecting differences between 
in-patients and out-patients. We assumed in-patients learn more about angina 
than out-patients. RESULTS: The ASMQ contained 12 items organized in two 
domains: risk-factor and self-management. The ASMQ was tested on 430 
patients (age 63±12 year; 171 male, 40%); Of those, 150 (35%) were outpatients, 
and 86 (20%) retested 24 hours later. Test-rest correlation coefficient of the ASMQ 
was 0.740, and 0.719, 0.780 for risk-factor and self-management domains 
respectively. Cronbach’s alpha coefficient was 0.616 of the overall questionnaire, 
and 0.692 of the self-management domain. But the risk-factor domain was 0.432, 
showed an unsatisfied internal consistency. Three factors were extracted 
through EFA, and were stratified into 2 domains as expected. The score of in-
patients (43±7) was higher than out-patients (41±6), which showed a better 
management among in-patients (p=0.017). CONCLUSIONS: The ASMQ showed an 
